A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (NCT07128199)

🧪 Interventions in This Study

• TAS6417 (DRUG)
• Zipalertinib Matching-placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (252 Sites)

Showing the first 25 of 252 sites.

• Alaska Oncology and Hematology — Anchorage, Alaska
• City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
• City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center — Irvine, California
• Scripps Clinic Torrey Pines — La Jolla, California
• Kaiser Permanente - Vallejo Medical Center — Vallejo, California
• Georgetown University School of Medicine — Washington D.C., District of Columbia
• D&H Cancer Research Center - Margate — Margate, Florida
• Alpha Oncology Research — Orange City, Florida
• City of Hope - Atlanta — Newnan, Georgia
• University of Illinois Medical Center — Chicago, Illinois
• Profound Research LLC at Michigan Hematology and Oncology Consultants — Dearborn, Michigan
• Henry Ford Health System — Detroit, Michigan
• Memorial Sloan Kettering Cancer Center - Basking Ridge — Basking Ridge, New Jersey
• Memorial Sloan Kettering Cancer Center - Monmouth — Middletown, New Jersey
• Memorial Sloan Kettering Cancer Center - Bergen — Montvale, New Jersey
• Memorial Sloan Kettering Cancer Center - Commack — Commack, New York
• Memorial Sloan Kettering Cancer Center - Westchester — East White Plains, New York
• Long Island Jewish Medical Center — Lake Success, New York
• Perlmutter Cancer Center - 34th Street — New York, New York
• Memorial Sloan Kettering Cancer Center - New York — New York, New York
• Memorial Sloan Kettering Cancer Center - Nassau — Uniondale, New York
• Atrium Health Wake Forest Baptist - Comprehensive Cancer Center — Charlotte, North Carolina
• Durham Veterans Affairs Health Care System — Durham, North Carolina
• Gabrail Cancer and Research Center — Canton, Ohio
• Gibbs Cancer Center and Research Institute Spartanburg — Spartanburg, South Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Cancer

• Implementation Strategies for Monitoring Adherence in Real Time — Philadelphia, Pennsylvania
• Early Detection of Lung Cancer — Nashville, Tennessee
• Improving Utilization of Lung Cancer Screening in Underserved PA Populations — Allentown, Pennsylvania
• Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting — Houston, Texas
• Testing the Engaged Approach to Lung Cancer Screening — Denver, Colorado
• Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer — Boston, Massachusetts

Explore by condition: All Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.